Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis

Diagnostic performance of 68Ga-PSMA PET/CT for restaging prostate cancer

Manuela Hoffmann, Helmut Wieler, Jonas Müller-Hübenthal, Ludwin Trampert, Matthias Miederer and Mathias Schreckenberger
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1568;
Manuela Hoffmann
2Supervisory Center for Medical Radiation Protection Bundeswehr Medical Service Headquarters Koblenz Germany
3Clinic of Nuclear Medicine Johannes Gutenberg-University Mainz Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helmut Wieler
1Clinic of Nuclear Medicine Bundeswehr Central Hospital Koblenz Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonas Müller-Hübenthal
5Praxis im KölnTriangle Köln Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludwin Trampert
4Clinic of Nuclear Medicine Klinikum Mutterhaus der Borromäerinnen Trier Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Miederer
3Clinic of Nuclear Medicine Johannes Gutenberg-University Mainz Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Schreckenberger
3Clinic of Nuclear Medicine Johannes Gutenberg-University Mainz Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1568

Objectives: The aim of this study is to evaluate 68Ga-PSMA PET/CT for detecting recurrent prostate carcinoma (PCa) in a large cohort of patients with biochemical recurrence (BCR) and to determine the best time for performing 68Ga-PSMA PET/CT scans.

Methods: We retrospectively studied 68Ga-PSMA-11-PET/CT scans of 556 patients with BCR of PCa which had previously been treated for localized cancer. BCR is defined as PSA (prostate-specific antigen) >0.2 ng/ml and rising. The performance of 68Ga-PSMA-11-PET/CT in relation to the PSA value at the time of the scans was assessed by receiver operating characteristic (ROC) curves generating by plotting sensitivity versus 1-specificity.

Results: 68Ga-PSMA-PET/CT revealed malignant prostatic lesions in 418/556 patients (75%). In our series, 93 PSMA-PET/CT scans were performed in patients with PSA levels between 1 and 2 ng/ml with a positivity rate of 73%. In this subpopulation, 68Ga-PSMA-PET/CT showed the presence of distant metastases in 17% (16 of 93) and of oligometastatic disease in 58% (54 of 93). The absolute PSA value at the time of the scan was associated with an increased probability of a positive 68Ga-PSMA-PET/CT scan (p<0.001). By means of ROC analysis a PSA value of 1.40 ng/ml was found to be the optimal cut off-level for predicting positive and negative scans (AUC=0.793; 95% CI 0.752-0.834). In patients with a PSA value <1.40 ng/ml, 53% (115/215) 68Ga-PSMA-PET/CT scans were positive, whereas patients with a PSA ≥1.40 ng/ml exhibited positive scan results in 89% (303/341) (p<0.001, r 0.399). Oligometastatic disease was determined in 44% (95/215) of patients with PSA levels below cut off-level vs. 69% (236/341) of patients with PSA above cut off (p<0.001, r 0.255).

Conclusions: This study demonstrates in a large population of patients, that 68Ga-PSMA-11-PET/CT is an excellent method for restaging PC, even in patients with low PSA levels. The PSA level was the main predictor of a positive scan with an optimal cut off-value of 1.40 ng/ml.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Diagnostic performance of 68Ga-PSMA PET/CT for restaging prostate cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Diagnostic performance of 68Ga-PSMA PET/CT for restaging prostate cancer
Manuela Hoffmann, Helmut Wieler, Jonas Müller-Hübenthal, Ludwin Trampert, Matthias Miederer, Mathias Schreckenberger
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1568;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Diagnostic performance of 68Ga-PSMA PET/CT for restaging prostate cancer
Manuela Hoffmann, Helmut Wieler, Jonas Müller-Hübenthal, Ludwin Trampert, Matthias Miederer, Mathias Schreckenberger
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1568;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

  • Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer
  • The value of 18F-FDG PET / MR in skull-base bone invasion of nasopharyngeal carcinoma
  • Prognostic value of tumor metabolic imaging phenotype using FDG PET radiomics in HNSCC
Show more Oncology: Clinical Therapy and Diagnosis

Prostate/GU Imaging Posters

  • [18F]-fluciclovine positivity rate is not affected by androgen deprivation therapy (ADT) in recurrent prostate cancer post-prostatectomy.
  • Test-retest study of tumor blood flow quantification with 82Rubidium-PET/CT in prostate cancer
  • Comparison of three interpretation criteria of 68Ga-PSMA PET based on inter- and intra-reader agreement
Show more Prostate/GU Imaging Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire